Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: Am J Physiol Endocri... - April 24, 2024 Category: Endocrinology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: American Journal of Physiology. Endocrinology and Metabolism - April 24, 2024 Category: Physiology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: Am J Physiol Endocri... - April 24, 2024 Category: Endocrinology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: American Journal of Physiology. Endocrinology and Metabolism - April 24, 2024 Category: Physiology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: Am J Physiol Endocri... - April 24, 2024 Category: Endocrinology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: American Journal of Physiology. Endocrinology and Metabolism - April 24, 2024 Category: Physiology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Chronic Pancreatitis-Associated Metabolic Bone Diseases: Epidemiology, Mechanisms, and Clinical Advances
Am J Physiol Endocrinol Metab. 2024 Apr 24. doi: 10.1152/ajpendo.00113.2024. Online ahead of print.ABSTRACTChronic pancreatitis (CP) is a progressive inflammatory disease with an increasing global prevalence. In recent years, a strong association between CP and metabolic bone diseases (MBDs), especially osteoporosis, has been identified, attracting significant attentions in the research field. Epidemiological data suggest a rising trend in the incidence of MBDs among CP patients. Notably, recent studies have highlighted a profound interplay between CP and altered nutritional and immune profiles, offering insights into its ...
Source: Am J Physiol Endocri... - April 24, 2024 Category: Endocrinology Authors: Tianlin Wang Ke Xiong Yanli He Binbin Feng Linbin Guo Jingliang Gu Hong Wang Xiaohao Wu Source Type: research
Targeting ferroptosis for treating kidney disease
AbstractFerroptosis is a type of regulated cell death hallmarked by iron-mediated excessive lipid oxidation. Over the past decade since the coining of the term ferroptosis, advances in research have led to the identification of intracellular processes that regulate ferroptosis such as GSH-GPX4 pathway and FSP1-coenzyme Q10/vitamin K pathway. From a disease perspective, the involvement of ferroptosis in pathological conditions including kidney disease has attracted attention. In terms of renal pathophysiology, ferroptosis has been widely investigated for its involvement in ischemia –reperfusion injury, nephrotoxin-induced...
Source: Clinical and Experimental Nephrology - April 22, 2024 Category: Urology & Nephrology Source Type: research
Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours
Arch Cardiovasc Dis. 2024 Apr 12:S1875-2136(24)00058-5. doi: 10.1016/j.acvd.2024.02.012. Online ahead of print.ABSTRACTAround 10% of patients with acute coronary syndrome are treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants for various indications. The initial management of these patients is highly complex, and new guidelines specify that, only during percutaneous coronary intervention, a bolus of unfractionated heparin is recommended in one of the following circumstances: (1) if the patient is receiving a non-vitamin K antagonist oral anticoagulant; or (2) if the international normalized ra...
Source: Archives of Cardiovascular Diseases - April 21, 2024 Category: Cardiology Authors: Alexandre Salaun Emmanuel de Maistre Marl ène Daller Chan Sombrun Fr édéric Chagué Florence Bichat Luc Rochette Nicolas Danchin Laurent Fauchier Marianne Zeller Yves Cottin Source Type: research
Performance of direct oral anticoagulant (DOAC) testing by hemostasis laboratories: The Australasian/Asia-Pacific experience
CONCLUSION: We hope our findings, reflecting on mostly consistent reporting of DOAC levels and interpretation provides reassurance for clinicians requesting these measurements, and helps support their implementation in regions where there is a paucity of test availability.PMID:38644463 | DOI:10.1111/ijlh.14288 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - April 21, 2024 Category: Hematology Authors: Emmanuel J Favaloro Sandya Arunachalam Elysse Dean Source Type: research
Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48hours
Arch Cardiovasc Dis. 2024 Apr 12:S1875-2136(24)00058-5. doi: 10.1016/j.acvd.2024.02.012. Online ahead of print.ABSTRACTAround 10% of patients with acute coronary syndrome are treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants for various indications. The initial management of these patients is highly complex, and new guidelines specify that, only during percutaneous coronary intervention, a bolus of unfractionated heparin is recommended in one of the following circumstances: (1) if the patient is receiving a non-vitamin K antagonist oral anticoagulant; or (2) if the international normalized ra...
Source: Archives of Cardiovascular Diseases - April 21, 2024 Category: Cardiology Authors: Alexandre Salaun Emmanuel de Maistre Marl ène Daller Chan Sombrun Fr édéric Chagué Florence Bichat Luc Rochette Nicolas Danchin Laurent Fauchier Marianne Zeller Yves Cottin Source Type: research
Response to “Characteristics of the prothrombotic milieu in mitral stenosis patients managed with direct oral anticoagulants”
We read Dr. Jolobe's valuable comments regarding our study. We believe that any recommendation on the utility of direct oral anticoagulants (DOACs) in mitral stenosis (MS) patients with atrial fibrillation (AF) should only be based on the recently published INVICTUS trial [1] providing reliable evidence on the superiority of vitamin K antagonists (VKAs) compared to DOACs. However, the excellent time-in-therapeutic-range in the VKA group in INVICTUS [1] is in contrast with the current real-world experience in countries with a high prevalence of rheumatic heart disease [2], which opens a debate on the transferability of INVI...
Source: International Journal of Cardiology - April 20, 2024 Category: Cardiology Authors: Parham Sadeghipour, Mohammadhossein Mozafarybazargany, Melody Farrashi, Raffaele De Caterina Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
New anticoagulants in 2024: Development of factor XI and XIa inhibitors
Ann Biol Clin (Paris). 2024 Apr 19;82(1):9-23. doi: 10.1684/abc.2024.1865.ABSTRACTThrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better saf...
Source: Annales de Biologie Clinique - April 19, 2024 Category: Biochemistry Authors: N ûn K Bentounes Sophie Melicine Anne-C éline Martin David M Smadja Nicolas Gendron Source Type: research
